Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Decline in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 42.2% from the January 31st total of 96,000 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average trading volume of 64,900 shares, the days-to-cover ratio is currently 0.9 days.

Lixte Biotechnology Trading Down 6.9 %

Shares of NASDAQ:LIXT traded down $0.09 during trading on Monday, hitting $1.21. 33,298 shares of the stock were exchanged, compared to its average volume of 317,221. The company has a fifty day moving average price of $2.09 and a two-hundred day moving average price of $1.95. The company has a market cap of $2.72 million, a PE ratio of -0.70 and a beta of -0.04. Lixte Biotechnology has a 12-month low of $1.21 and a 12-month high of $4.40.

Institutional Investors Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. Atlas Legacy Advisors LLC acquired a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology at the end of the most recent reporting period. Institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.